Progelife Company Profile: Valuation & Investors

Progelife Overview

Founded
2014

Status
Private

Employees
10

Latest Deal Type
Later Stage VC

Latest Deal Amount
$881K

Investors
1

Progelife General Information

Description

Operator of a biotechnology company intended to develop drugs for the treatment of rare genetic aging diseases. The company designs patented therapeutics whose molecules are identified and validated for rare genetic diseases and are transposed to more frequent pathologies linked to the generalized aging of the population, enabling children and patients suffering from certain skin cancers to get proper treatments.

Contact Information

Website

www.progelife.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology

Primary Office

OBRATORI-CISAM
61 Boulevard des Dames
13002 Marseille
France



Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Progelife Valuation & Funding

Deal Type	Date	Amount	Raised to Date	Post-Val	Status	Stage
3. Later Stage VC	03-Mar-2020	$881K	00.000	000.00	Completed	Generating Revenue
2. Seed Round	08-Mar-2019	00000	00000		Completed	Startup
1. Accelerator/Incubator					Completed	Startup

To view Progelife’s complete valuation and funding history, request access »

Progelife Cap Table

Stock	# of Shares Authorized	Par Value	Dividend Rate (%)	Original Issue Price	Liquidation	Liquidation Pref. Multiple	Conversion Price	% Owned
Ordinary	0,000	00.000000		0000.00	0000.00	00	0000.00	0.000

To view Progelife’s complete cap table history, request access »

Progelife Executive Team (5)

Name	Title	Board Seat	Contact Info
Frederic Beneton	Chief Executive Officer, Managing Director & President
Pierre Cau Ph.D	Co-Founder & Scientific Director
Eric Dessaud Ph.D	CSO
Nicolas Lévy Ph.D	Co-Founder